BAM Wealth Management LLC Makes New $901,000 Investment in Thermo Fisher Scientific Inc. $TMO

BAM Wealth Management LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,858 shares of the medical research company’s stock, valued at approximately $901,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares during the last quarter. U.S. Capital Wealth Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 5.6% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 1,779 shares of the medical research company’s stock worth $721,000 after acquiring an additional 95 shares during the period. Accurate Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 15.5% in the second quarter. Accurate Wealth Management LLC now owns 789 shares of the medical research company’s stock worth $338,000 after acquiring an additional 106 shares during the last quarter. Finally, Old North State Wealth Management LLC increased its position in Thermo Fisher Scientific by 24.1% during the second quarter. Old North State Wealth Management LLC now owns 804 shares of the medical research company’s stock worth $327,000 after purchasing an additional 156 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Barclays boosted their price objective on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Leerink Partners boosted their price target on Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a research report on Wednesday, October 22nd. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Friday. UBS Group boosted their target price on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Finally, TD Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $625.47.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $625.42 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The stock’s 50 day moving average price is $590.88 and its 200 day moving average price is $530.87. The firm has a market capitalization of $234.98 billion, a PE ratio of 36.13, a price-to-earnings-growth ratio of 4.21 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $5.28 earnings per share. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific announced that its board has authorized a stock buyback program on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Insider Activity at Thermo Fisher Scientific

In related news, VP Lisa P. Britt sold 1,058 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total value of $622,379.08. Following the transaction, the vice president owned 13,087 shares in the company, valued at approximately $7,698,558.62. The trade was a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael D. Shafer sold 10,725 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total value of $6,435,000.00. Following the sale, the executive vice president owned 18,731 shares of the company’s stock, valued at approximately $11,238,600. This trade represents a 36.41% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 131,767 shares of company stock valued at $76,467,793. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.